Fresenius Targets Nostrum’s Generic PhosLo GelCaps

Law360, New York (January 17, 2012, 2:44 PM EST) -- Fresenius Medical Care Holdings Inc. on Friday lodged a patent infringement suit in Massachusetts federal court in an effort to block Nostrum Laboratories Inc. from marketing a generic version of kidney failure treatment PhosLo GelCaps.

Fresenius lodged the suit after Nostrum filed an abbreviated new drug application with the U.S. Food and Drug Administration to sell a calcium acetate drug — the generic form of PhosLo GelCaps — which is used in end-stage renal failure to boost calcium levels and combat high levels of phosphate in...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.